EBITDA Margin % is calculated as EBITDA divided by its Revenue. TFBS Bioscience's EBITDA for the
six
months ended in Dec. 2025 was NT$-6.2 Mil. TFBS Bioscience's Revenue for the
six
months ended in Dec. 2025 was NT$106.2 Mil. Therefore, TFBS Bioscience's EBITDA margin for the quarter that ended in Dec. 2025 was -5.87%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TFBS Bioscience EBITDA Margin % Related Terms
TFBS Bioscience EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TFBS Bioscience's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6939 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, TFBS Bioscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TFBS Bioscience EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, TFBS Bioscience's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TFBS Bioscience's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TFBS Bioscience (ROCO:6939) has a EBITDA Margin % of -5.87% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TFBS Bioscience and its competitors. According to the industry distribution chart, TFBS Bioscience ranks #131 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 64.2%.
Is TFBS Bioscience's EBITDA Margin % too high?
TFBS Bioscience's current EBITDA Margin % is -5.87%. Based on the distribution chart, TFBS Bioscience ranks #131 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, TFBS Bioscience has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TFBS Bioscience's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, TFBS Bioscience ranks #131 out of 204 companies for EBITDA Margin %. This places TFBS Bioscience in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TFBS Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TFBS Bioscience's current EBITDA Margin % is -5.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TFBS Bioscience stock overvalued right now?
Based on GuruFocus' analysis, TFBS Bioscience (ROCO:6939) is currently considered Possible Value Trap. The stock's GF Value™ is NT$32.17, compared to a current price of NT$20.60 — trading 36% below its estimated fair value. The current EBITDA Margin % is -5.87%. TFBS Bioscience's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TFBS Bioscience (ROCO:6939), the current EBITDA Margin % is -5.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TFBS Bioscience (ROCO:6939) Overvalued in 2026?
Based on GuruFocus' analysis, TFBS Bioscience stock appears to be undervalued.
The current stock price of NT$20.60 is trading 36% below its estimated GF Value™ of NT$32.17.
GuruFocus considers TFBS Bioscience to be Possible Value Trap.
Key valuation signals for ROCO:6939:
EBITDA Margin %: -5.87%
GF Value™: NT$32.17 vs. price of NT$20.60 (36% below fair value)
No single metric tells the full story. See the ROCO:6939 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TFBS Bioscience Inc is a Contract Research Organization (CRO) providing biological testing in Taiwan. Its services include viral vector manufacturing for cell and gene therapy products and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.
49GF Score
Get the complete analysis for ROCO:6939
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6939 has been successfully added to your 
